Full-Life Technologies secures $150M Series D financing
read at Endpoints ↗DealNeutral
Full-Life Technologies announced it has raised $150 million in a Series D financing round, comprising $110 million in the main tranche and an additional $40 million.
The capital is intended to advance the company’s radiotherapy platform and support broader commercial and development activities.
The brief also referenced other biotech updates, including Quince’s renewed focus on a pulmonary drug and news involving Accro Bioscience, Hansa Biopharma, Shanghai Best-Link Bioscience and UCB, though no further details were provided.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Full-Life Technologies raises $150M; Quince's reboot with pulmonary drug”
read at Endpoints ↗74 words · retrieved May 19
comments(0)
5-min edit window · permanent after that